MetaVia Inc公布其与Syntekabio持续合作中人工智能建模研究的积极成果。最新数据证实，双方共同开发的糖尿病肾病治疗药物Vanoglipel已通过AI模型精准锁定关键治疗靶点。
这项突破性进展标志着AI驱动药物研发模式在复杂疾病领域的应用迈出重要一步。通过深度学习算法分析海量生物医学数据，研究团队成功验证了Vanoglipel作用于肾脏纤维化与炎症通路的核心机制。
合作双方表示，该成果将显著加速Vanoglipel的临床前开发进程。AI建模不仅缩短了传统靶点确认周期，更通过多维度模拟预测了化合物与靶点相互作用的特异性，为后续药物优化提供重要依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.